Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 5, 2004 - Issue 11
Submit an article Journal homepage
324
Views
61
CrossRef citations to date
0
Altmetric
Review

Pharmacological treatment of nephropathic cystinosis with cysteamine

Robert Kleta NHGRI, Building 10, Room 10C-107, MSC 1851, 10 Center Drive, Bethesda, MD 20892, USA. [email protected]
&
William A Gahl National Institutes of Health, Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD, USA
Pages 2255-2262 | Published online: 25 Feb 2005

Bibliography

  • GAHL WA, BASHAN N, TIETZE F, BERNARDINI I, SCHULMAN JD: Lysosomal cystine transport is defective in cystinosis. Science (1982) 217(4566):1263–1265.
  • TOWN M, JEAN G, CHERQUI S et al: A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat. Genet. (1998) 18(4):319–324.
  • GAHL WA, THOENE J, SCHNEIDER JA: Cystinosis: a disorder of lysosomal membrane transport. In: The Metabolic & Molecular Bases of Inherited Disease (Volume III). Scriver CR, Beaudet AL, Valle D, Sly WS (Eds), 8th edn, McGraw-Hill, New York, USA (2001):5085–5108.
  • ••A comprehensive review of cystinosis.
  • GAHL WA, THOENE JG, SCHNEIDER JA: Cystinosis. N Engl. Med. (2002) 347(2):111–121.
  • ••A thorough clinical discussion ofcystinosis.
  • THE CYSTINOSIS COLLABORATIVE RESEARCH GROUP: Linkage of the gene for cystinosis to markers on the short arm of chromosome 17. Nat. Genet. (1995) 10(2):246–248.
  • SHOTELERSUK V, LARSON D, ANIKSTER Y et al.: CTNS mutations in an American-based population of cystinosis patients. Am..): Hum. Genet. (1998) 63(5):1352–1362.
  • ANIKSTER Y, LUCERO C, TOUCHMAN JW et al.: Identification and detection of the common 65-kb deletion breakpoint in the nephropathic cystinosis gene (CTNS). Ma Genet. Metab. (1999) 66(2):111–116.
  • FORESTIER L, JEAN G, ATTARD M et al.: Molecular characterization of CTNS deletions in nephropathic cystinosis: development of a PCR-based detection assay. Am. J. Hum. Genet. (1999) 65(2):353–359.
  • TOUCHMAN JW, ANIKSTER Y, DIETRICH NL et al.: The genomic region encompassing the nephropathic cystinosis gene (CTNS): complete sequencing of a 200-kb segment and discovery of a novel gene within the common cystinosis-causing deletion. Genome Res. (2000) 10(2):165–173.
  • ANIKSTER Y, LUCERO C, GUO J et al.: Ocular nonnephropathic cystinosis: clinical, biochemical, and molecular correlations. Pediatr. Res. (2000) 47(1):17–23.
  • GRETZ N, MANZ F, AUGUSTIN R et al.: Survival time in cystinosis. A collaborative study. Proc. Eur. Dial. Transplant. Assoc. (1983) 19:582–589.
  • THEODOROPOULOS DS, KRASNEWICH D, KAISERKUPFER MI, GAHL WA: Classical nephropathic cystinosis as an adult disease. JAMA (1993) 270(18):2200–2204.
  • GAHL WA, DALAKAS MC, CHARNAS L et al: Myopathy and cystine storage in muscles in a patient with nephropathic cystinosis. N Engl. I Med. (1988) 319(22):1461–1464.
  • CHARNAS LR, LUCIANO CA, DALAKAS M et al.: Distal vacuolar myopathy in nephropathic cystinosis. Ann. Neurol (1994) 35(2):181–188.
  • SONIES BC, EKMAN EF, ANDERSSON HC et al: Swallowing dysfunction in nephropathic cystinosis. N. Engl. J. Med. (1990) 323(9):565–570.
  • KAISER-KUPFER MI, CARUSO RC, MINKLER DS, GAHL WA: Long-term ocular manifestations in nephropathic cystinosis. Arch. Ophthalmol (1986) 104(5):706–711.
  • FIVUSH B, GREEN OC, PORTER CC, BALFE JW, O'REGAN S, GAHL WA: Pancreatic endocrine insufficiency in posttransplant cystinosis. Am. Dis. Child. (1987) 141(10):1087–1089.
  • FIVUSH B, FLICK JA, GAHL WA: Pancreatic exocrine insufficiency in a patient with nephropathic cystinosis. Pediatr. (1988) 112(1):49–51.
  • ANIKSTER Y, LACBAWAN F, BRANTLY M et al.: Pulmonary dysfunction in adults with nephropathic cystinosis. Chest (2001) 119(2):394–401.
  • CHIK CL, FRIEDMAN A, MERRIAM GR, GAHL WA: Pituitary-testicular function in nephropathic cystinosis. Ann. Intern. Med. (1993) 119(7 Pt 1):568–575.
  • EHRICH JH, STOEPPLER L, OFFNER G, BRODEHL J: Evidence for cerebral involvement in nephropathic cystinosis. Neuropadiatrie (1979) 10(2):128–137.
  • FINK JK, BROUWERS P, BARTON N et al.: Neurologic complications in long-standing nephropathic cystinosis. Arch. Neurol (1989) 46(5):543–548.
  • GAHL WA, TIETZE F, BUTLER JD, SCHULMAN JD: Cysteamine depletes cystinotic leucocyte granular fractions of cystine by the mechanism of disulphide interchange. Biochem. J. (1985) 228(3):545–550.
  • PISONI RL, THOENE JG, CHRISTENSEN HN: Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts. Biol. Chem. (1985) 260(8):4791–4798.
  • THOENE JG, OSHIMA RG, CRAWHALL JC, OLSON DL, SCHNEIDER JA: Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. I Clin. Invest. (1976) 58(1):180–189.
  • GAHL WA, REED GF, THOENE JG et al.: Cysteamine therapy for children with nephropathic cystinosis. N Engl. I Med. (1987) 316(16):971–977.
  • MARKELLO TC, BERNARDINI IM, GAHL WA: Improved renal function in children with cystinosis treated with cysteamine. N Engl. J. Med. (1993) 328(16):1157–1162.
  • KIMONIS VE, TROENDLE J, YANG ML et al.: Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. I Clin. Endocrinol Metab. (1995) 80(11):3257–3261.
  • KAISER-KUPFER MI, FUJIKAWA L, KUWABARA T, GAHL WA: Removal of corneal crystals by topical cysteamine in nephropathic cystinosis. N Engl. I Med. (1987) 316(13):775–779.
  • KAISER-KUPFER MI, GAZZO MA, DATILES MB et al.: A randomized placebo-controlled trial of cysteamine eyedrops in nephropathic cystinosis. Arch. Ophthalmol (1990) 108(5):689–693.
  • GAHL WA, KUEHL EM, NVATA F, LINDBLAD A, KAISER-KUPFER MI: Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Ma Genet. Metab. (2000) 71(1-2):100–120.
  • GAHL WA: Early oral cysteamine therapyfor nephropathic cystinosis. Eur: I Pediatr. (2003) 162\(Suppl. 1):538–541.
  • KLETA R, BERNARDINI I, UEDA M et al.: Long-term follow-up of well-treated nephropathic cystinosis patients. (2004) Pediatr. (In Press).
  • •A case report documenting the benefit of diligent treatment with cysteamine.
  • SMOLIN LA, CLARK KF, SCHNEIDER JA: An improved method for heterozygote detection of cystinosis, using polymorphonuclear leukocytes. Am. Hum. Genet. (1987) 41(2):266–275.
  • SMITH ML, PELLETT OL, CASS MM et al.: Prenatal diagnosis of cystinosis utilizing chorionic villus sampling. Prenat. Diagn. (1987) 7(1):23–26.
  • BENDAVID C, KLETA R, LONG R et al.: FISH diagnosis of the common 57-kb deletion in CTNS causing cystinosis. Human Genet. (2004) (In Press).
  • CHERQUI S, SEVIN C, HAMARD G et al.: Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis. Ma Cell. Biol. (2002) 22(21):7622–7632.
  • PARK M, HELIP-WOOLEY A, THOENE J: Lysosomal cystine storage augments apoptosis in cultured human fibroblasts and renal tubular epithelial cells. J. Am. Soc. Nephrol (2002) 13(12):2878–2887.
  • YUDKOFF M, FOREMAN JW, SEGAL S: Effects of cysteamine therapy in nephropathic cystinosis. N Engl. I Med. (1981) 304(3):141–145.
  • GAHL WA, THOENE JG, SCHNEIDER JA et al: NIH conference. Cystinosis: progress in a prototypic disease. Ann. Intern. Med. (1988) 109(7):557–569.
  • GAHL WA, CHARNAS L, MARKELLO TC et al.: Parenchymal organ cystine depletion with long-term cysteamine therapy. Biochem. Med. Metab. Biol. (1992) 48(3):275–285.
  • DA SILVA VA, ZURBRUGG RP, LAVANCHY P et al.: Long-term treatment of infantile nephropathic cystinosis with cysteamine. N Engl. I Med. (1985) 313(23):1460–1463.
  • VANT HOFF WG, GRETZ N: The treatment of cystinosis with cysteamine and phosphocysteamine in the United Kingdom and Eire. Pediatr. Nephrol (1995) 9(6):685–689.
  • NIAUDET P, TETE MJ, BROYER M: Renal disease in cystinosis. In: Cystinosis. Broyer M (Ed.), Elsevier, Paris, France (1999):36–41.
  • PROESMANS W, BATEN E, HOOGMARTENS J, BRUYNEEL P: Nephropathic cystinosis: effect of long-term cysteamine therapy. Clin. Nephrol. (1987) 27(6):309–312.
  • SCHNEIDER JA: Treatment of cystinosis: Simple in principle, difficult in practice. (2004) Pediatr. (In Press).
  • Cysteamine for cystinosis. Med. Lett. Drugs The]: (1994) 36(938):118.
  • SCHNEIDER JA: Approval of cysteamine for patients with cystinosis. Pediatr. Nephrol. (1995) 9(2):254.
  • KLETA R, GAHL WA: Cystinosis: antibodies and healthy bodies. Am. Soc. Nephrol. (2002) 13(8):2189–2191.
  • SKOVBY F, KLETA R, ANIKSTER Y, CHRISTENSEN R, GAHL WA: Cystinosis in Denmark: Mutation analysis and treatment with cystamine, the disulfide of cysteamine. Am.,/ Hum. Genet. (2002) 71(4):5413 (Abstract).
  • IWATA F, KUEHL EM, REED GF et al: A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis. Mol Genet. Metal,. (1998) 64(4):237–242.
  • TSILOU ET, THOMPSON D, LINDBLAD AS et al: A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis. Br. J. Ophthalmol. (2003) 87(1):28–31.
  • TENNEZE L, DAURAT V, TIBI A, CHAUMET-RIFFAUD P, FUNCK-BRENTANO C: A study of the relative bioavailabifity of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers. Br: J. Clin. Pharmacol (1999) 47(1):49–52.
  • BELLDINA EB, HUANG MY, SCHNEIDER JA, BRUNDAGE RC, TRACY TS: Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. Br. J. Clin. Pharmacol (2003) 56(5):520–525.
  • WENNER WJ, MURPHY JL: The effects of cysteamine on the upper gastrointestinal tract of children with cystinosis. Pediatr. Nephrol (1997) 11(5):600–603.
  • DOHIL R, NEWBURY RO, SELLERS ZM, DEUTSCH R, SCHNEIDER JA: The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. Pediatr. (2003) 143(2):224–230.
  • CORDEN BJ, SCHULMAN JD, SCHNEIDER JA, THOENE JG: Adverse reactions to oral cysteamine use in nephropathic cystinosis. Dev. Pharmacol Ther: (1981) 3(1):25–30.
  • BECKMAN DA, MULLIN JJ, ASSADI FK: Developmental toxicity of cysteamine in the rat: effects on embryo-fetal development. Teratology (1998) 58(3-4):96–102.
  • SOOHOO N, SCHNEIDER JA, KAPLAN RM: A cost-effectiveness analysis of the orphan drug cysteamine in the treatment of infantile cystinosis. Med. Decis. Making (1997) 17(2):193–198.
  • MEWISSEN DJ, BRUCER M: Late effects of gamma radiation on mice protected with cysteamine or cystamine. Nature (1957) 179(4552):201–202.
  • RAY-CHAUDHURI SP, CHAUDHURI JP, CHATTERJEE S: Cysteamine protection of grasshopper chromosomes from X-ray-induced aberrations under aerobic and anaerobic conditions. Int. .1. Radial-. Biol. (1962) 5(6):591–595.
  • OSHIMA RG, WILLIS RC, FURLONG CE, SCHNEIDER JA: Binding assays for amino acids. The utilization of a cystine binding protein from Escherichia coli for the determination of acid-soluble cystine in small physiological samples. J. Biol. Chem. (1974) 249(19):6033–6039.
  • KLETA R, ANIKSTER Y, LUCERO C et al.: CTNS mutations in African American patients with cystinosis. Ma Genet. Metal,. (2001) 74(3):332–337.
  • WINBERG J: The 24-hour true endogenous creatinine clearance in infants and children without renal disease. Acta Paediatr. (1959) 48:443–452.

Websits

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.